Prescribing information and Adverse event reporting can be found at the bottom of the page

This website is intended for Great Britain healthcare professionals only

Episode 1 – Why treat with Xofigo?

Listen to experts in the field as they discuss the benefits and challenges of treatment with radium-223 dichloride and why they consider it as an option for eligible mCRPC patients in their clinics.



  • Dr Omi Parikh - Consultant Clinical Oncologist
  • Ellie Cradock Molecular Radiotherapy Manager


Video title

YYMMDD Author/Uploaded by

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

This promotional podcast series has been initiated and funded by Bayer and is for healthcare professionals only.

XOFIGO▼ (radium-223 dichloride) Prescribing Information can be found here.

Reflective learning guide

Download Reflective Learning Guide


Dr Omi Parikh

Dr Omi Parikh


Consultant Clinical Oncologist at the Lancashire Teaching Hospitals NHS Foundation Trust and is Chair of the Lancashire & South Cumbria Urology Network Site Specific Group.


Dr Parikh completed her undergraduate medical training at the University of Edinburgh and her general medical training in Edinburgh and London. Following this, she undertook her specialist registrar training in London and registered in 1999. Her interests are urological cancers. In the past 15 years, she has co-authored over 30 peer reviewed articles and has expertise in prostate cancer, renal cell carcinoma, and bladder cancer. Dr Parikh is an investigator in multiple prostate, bladder and renal cancer trials and is involved in phase 1, 2 and 3 trials.

Ellie Cradock

Ellie Cradock


Lead Molecular Radiotherapy Manager at the University Hospitals Bristol NHS Foundation Trust.


Ellie trained as a Therapeutic Radiographer and has over 10 years’ experience working on linear accelerators, understanding the patient experience of a cancer diagnosis and how to provide holistic support through a treatment journey. Ellie has worked in Molecular Radiotherapy since 2015 and has had the privilege of setting up both Molecular Radiotherapy trials as well as new services in close collaboration with the many supporting departments that help make a complex service, such as this, work.

Optimising patient identification and referral

Episode 2 – Optimising patient identification and referral

The Practicalities of Treatment

Episode 3 – The Practicalities of Treatment

Want to stay in touch?

If you would like us to keep you up to date with details of future webinars and other important news updates, please stay connected using the button below.


Report Adverse Events
Adverse events should be reported. Reporting forms and information can be found at or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc Tel: 01182 063 500, Fax: 01182 063 703, Email:


If You Want to Report a Quality Complaint
Please report any quality complaint to Bayer Plc Email: For more information on how we process any personal data you share with us in relation to the above please see our Privacy Policy.